[1] |
Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision[J]. Am J Med Genet A, 2019, 179(12): 2393-2419.
doi: 10.1002/ajmg.a.61366
pmid: 31633310
|
[2] |
Ürel-Demir G, Şimşek-Kiper PÖ, Öncel İ, et al. Natural history of TRPV4-related disorders: from skeletal dysplasia to neuromuscular phenotype[J]. Eur J Paediatr Neurol, 2021, 32: 46-55.
doi: 10.1016/j.ejpn.2021.03.011
|
[3] |
Nishimura G, Lausch E, Savarirayan R, et al. TRPV4-associated skeletal dysplasias[J]. Am J Med Genet C Semin Med Genet, 2012, 160C(3): 190-204.
doi: 10.1002/ajmg.c.v160c.3
|
[4] |
Geneviève D, Le Merrer M, Feingold J, et al. Revisiting metatropic dysplasia: presentation of a series of 19 novel patients and review of the literature[J]. Am J Med Genet A, 2008, 146A(8): 992-996.
doi: 10.1002/ajmg.a.32191
pmid: 18348257
|
[5] |
Krakow D, Vriens J, Camacho N, et al. Mutations in the gene encoding the calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, Kozlowski type and metatropic dysplasia[J]. Am J Hum Genet, 2009, 84(3): 307-315.
doi: 10.1016/j.ajhg.2009.01.021
pmid: 19232556
|
[6] |
Rock MJ, Prenen J, Funari VA, et al. Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia[J]. Nat Genet, 2008, 40(8): 999-1003.
doi: 10.1038/ng.166
|
[7] |
Nishimura G, Dai J, Lausch E, et al. Spondylo-epiphyseal dysplasia, Maroteaux type (pseudo-Morquio syndrome type 2), and parastremmatic dysplasia are caused by TRPV4 mutations[J]. Am J Med Genet A, 2010, 152A(6): 1443-1449.
doi: 10.1002/ajmg.a.33414
pmid: 20503319
|
[8] |
Lamandé SR, Yuan Y, Gresshoff IL, et al. Mutations in TRPV4 cause an inherited arthropathy of hands and feet[J]. Nat Genet, 2011, 43(11): 1142-1146.
doi: 10.1038/ng.945
|
[9] |
White JP, Cibelli M, Urban L, et al. TRPV4: molecular conductor of a diverse orchestra[J]. Physiol Rev, 2016, 96(3): 911-973.
doi: 10.1152/physrev.00016.2015
pmid: 27252279
|
[10] |
Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: from structure to disease[J]. Prog Biophys Mol Biol, 2010, 103(1): 2-17.
doi: 10.1016/j.pbiomolbio.2009.10.002
|
[11] |
Arniges M, Fernández-Fernández JM, Albrecht N, et al. Human TRPV4 channel splice variants revealed a key role of ankyrin domains in multimerization and trafficking[J]. J Biol Chem, 2006, 281(3): 1580-1586.
doi: 10.1074/jbc.M511456200
pmid: 16293632
|
[12] |
Deng Z, Paknejad N, Maksaev G, et al. Cryo-EM and X-ray structures of TRPV4 reveal insight into ion permeation and gating mechanisms[J]. Nat Struct Mol Biol, 2018, 25(3): 252-260.
doi: 10.1038/s41594-018-0037-5
pmid: 29483651
|
[13] |
Loukin SH, Teng J, Kung C. A channelopathy mechanism revealed by direct calmodulin activation of TrpV4[J]. Proc Natl Acad Sci U S A, 2015, 112(30): 9400-9405.
doi: 10.1073/pnas.1510602112
|
[14] |
Strotmann R, Schultz G, Plant TD. Ca2+-dependent potentiation of the nonselective cation channel TRPV4 is mediated by a C-terminal calmodulin binding site[J]. J Biol Chem, 2003, 278(29): 26541-26549.
doi: 10.1074/jbc.M302590200
pmid: 12724311
|
[15] |
Ji C, McCulloch CA. TRPV4 integrates matrix mecha-nosensing with Ca2+ signaling to regulate extracellular matrix remodeling[J]. FEBS J, 2021, 288(20): 5867-5887.
doi: 10.1111/febs.v288.20
|
[16] |
Toft-Bertelsen TL, MacAulay N. TRPing to the point of clarity: understanding the function of the complex TRPV4 ion channel[J]. Cells, 2021, 10(1): 165.
doi: 10.3390/cells10010165
|
[17] |
Camacho N, Krakow D, Johnykutty S, et al. Dominant TRPV4 mutations in nonlethal and lethal metatropic dysplasia[J]. Am J Med Genet A, 2010, 152A(5): 1169-1177.
doi: 10.1002/ajmg.a.v152a:5
|
[18] |
Dicks AR, Maksaev GI, Harissa Z, et al. Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes[J]. Elife, 2023, 12: e71154.
doi: 10.7554/eLife.71154
|
[19] |
Hou W, Fu H, Liu X, et al. Cation channel transient receptor potential vanilloid 4 mediates topography-induced osteoblastic differentiation of bone marrow stem cells[J]. ACS Biomater Sci Eng, 2019, 5(12): 6520-6529.
doi: 10.1021/acsbiomaterials.9b01237
|
[20] |
Clark AL, Votta BJ, Kumar S, et al. Chondroprotective role of the osmotically sensitive ion channel transient receptor potential vanilloid 4: age- and sex-dependent progression of osteoarthritis in Trpv4-deficient mice[J]. Arthritis Rheum, 2010, 62(10): 2973-2983.
doi: 10.1002/art.v62:10
|
[21] |
Willard VP, Leddy HA, Palmer D, et al. Transient receptor potential vanilloid 4 as a regulator of induced pluripotent stem cell chondrogenesis[J]. Stem Cells, 2021, 39(11): 1447-1456.
doi: 10.1002/stem.3440
pmid: 34427363
|
[22] |
Rorden C, Griswold MC, Moses N, et al. Radiographical survey of osteochondrodysplasia in Scottish Fold cats caused by the TRPV4 gene variant[J]. Hum Genet, 2021, 140(11): 1525-1534.
doi: 10.1007/s00439-021-02337-5
pmid: 34406467
|
[23] |
Ji C, Mcculloch CA. TRPV4 integrates matrix mechanosensing with Ca2+ signaling to regulate extracellular matrix remodeling[J]. FEBS J, 2021, 288(20): 5867-5887.
doi: 10.1111/febs.v288.20
|
[24] |
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424.
doi: 10.1038/gim.2015.30
pmid: 25741868
|
[25] |
Nishimura G, Kizu R, Kijima Y, et al. Spondyloepiphyseal dysplasia Maroteaux type: report of three patients from two families and exclusion of type II collagen defects[J]. Am J Med Genet A, 2003, 120A(4): 498-502.
pmid: 12884428
|
[26] |
Nemec SF, Cohn DH, Krakow D, et al. The importance of conventional radiography in the mutational analysis of skeletal dysplasias (the TRPV4 mutational family)[J]. Pediatr Radiol, 2012, 42(1): 15-23.
doi: 10.1007/s00247-011-2229-6
|
[27] |
Kozlowski K. La dysostose spondylometaphysaire[M]. Presse Méd., 1967, 75: 2769-2774.
|
[28] |
Poznanski AK. Progress in pediatric radiology[M]. Vol. 4: Intrinsic Diseases of Bones:The Radiological Society of North America, 1973.
|
[29] |
Kannu P, Aftimos S, Mayne V, et al. Metatropic dysplasia: clinical and radiographic findings in 11 patients demonstrating long-term natural history[J]. Am J Med Genet A, 2007, 143A(21): 2512-2522.
pmid: 17879966
|
[30] |
Geneviève D, Le Merrer M, Munnich A, et al. Long-term follow-up in a patient with metatropic dysplasia[J]. Am J Med Genet A, 2005, 135(3): 342-343.
pmid: 15889420
|
[31] |
Vriens J, Owsianik G, Janssens A, et al. Determinants of 4 alpha-phorbol sensitivity in transmembrane domains 3 and 4 of the cation channel TRPV4[J]. J Biol Chem, 2007, 282(17): 12796-12803.
doi: 10.1074/jbc.M610485200
pmid: 17341586
|
[32] |
Klausen TK, Pagani A, Minassi A, et al. Modulation of the transient receptor potential vanilloid channel TRPV4 by 4alpha-phorbol esters: a structure-activity study[J]. J Med Chem, 2009, 52(9): 2933-2939.
doi: 10.1021/jm9001007
pmid: 19361196
|
[33] |
McCray BA, Schindler A, Hoover-Fong JE, et al. Autosomal dominant TRPV4 disorders[DB/OL]. GeneReviews® [Internet]: University of Washington, Seattle, 2020.
|
[34] |
袁佳雨, 孙东兰, 李亚洲. TRPV4基因的两个不同变异导致变形性骨发育不良表型严重程度差异[J]. 中国组织化学与细胞化学杂志, 2021, 30(6): 545-551.
|